Saltar al contenido
Merck

50495521

Supelco

Discovery® C18 (5 µm) HPLC Columns

L × I.D. 15 cm × 2.1 mm, HPLC Column

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501

product name

Columna para HPLC Discovery® C18, 5 μm particle size, L × I.D. 15 cm × 2.1 mm

agency

suitable for USP L1

feature

endcapped

extent of labeling

12% Carbon loading

parameter

≤70 °C temp. range

technique(s)

HPLC: suitable

L × I.D.

15 cm × 2.1 mm

surface area

300 m2/g

surface coverage

3 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical particle platform

matrix active group

C18 (octadecyl) phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

separation technique

reversed phase

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

Utilice Discovery® C18 para cualquier método que especifique una C18. La forma del pico, la reproducibilidad y la estabilidad excepcionales hacen de ella la columna de elección para todos los métodos C18, desde los más exigentes hasta los rutinarios.

Features and Benefits

  • Excelente reproducibilidad
  • Excepcional forma del pico para analitos básicos y ácidos
  • Separaciones LC-MS estables con poco sangrado
  • Separación de péptidos y proteínas pequeñas
  • Menor hidrofobicidad que muchas columnas C 18 comparables, proporcionando análisis más rápidos

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

guard cartridge

Referencia del producto
Descripción
Precios

Storage Class

11 - Combustible Solids

wgk_germany

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificados de análisis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

T R Shantha Kumar et al.
Journal of pharmaceutical and biomedical analysis, 38(1), 173-179 (2005-05-24)
A simple, precise and accurate isocratic reverse-phase liquid chromatography method with programmed wavelength detection has been validated to quantify DRF-4367 and Phenol red, simultaneously for application in rat in situ single pass intestinal perfusion study to assess intestinal permeability of
Himal Paudel Chhetri et al.
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 22(5), 483-487 (2014-12-05)
This study presents the optimization of a simple HPLC-UV method for the determination of metformin in human plasma. Ion pair separation followed by UV detection was performed on deproteinized human plasma samples. The separation was carried out on a Discovery
Ramisetti Nageswara Rao et al.
Journal of separation science, 32(9), 1312-1322 (2009-04-29)
Modafinil, adrafinil and their related substances were synthesized and analyzed by RP-LC with ESI-MS/MS. The ionization mode, polarity, cone voltage, and chromatographic conditions were evaluated. The optimum LC-MS conditions to obtain fragment ions indispensable for identification of the structures were
Abbas Khan et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 879(24), 2423-2429 (2011-07-26)
A novel isocratic reversed-phase high performance liquid-chromatography/ultraviolet detection method for simultaneous determination of cefdinir and cefixime in human plasma was developed and validated after optimization of various chromatographic conditions and other experimental parameters. Sample preparation based on a simple extraction
Sheelendra Pratap Singh et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 879(27), 2845-2851 (2011-09-06)
Tamoxifen is the agent of choice for the treatment of estrogen receptor-positive breast cancer. Tamoxifen is a substrate of P-glycoprotein (P-gp) and microsomal cytochrome P450 (CYP) 3A, and biochanin A (BCA) is an inhibitor of P-gp and CYP3A. Hence, it

Contenido relacionado

Discovery C18 and C8 HPLC Columns products offered

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico